Core Viewpoint - The company reported a decline in revenue and net profit for Q3 2025, leading to a downward revision of profit forecasts for 2025-2027, while maintaining a "buy" rating due to a rich product matrix and ongoing internationalization efforts [1][2]. Financial Performance - For the first three quarters of 2025, the company achieved revenue of 1.87 billion yuan, a year-on-year decrease of 21.5%, and a net profit attributable to shareholders of 1.09 billion yuan, down 31.1% [1]. - In Q3 alone, revenue was 570 million yuan, a decline of 21.3%, with a net profit of 300 million yuan, down 34.6% [1]. - The gross margin for Q1-Q3 2025 was 93.4%, slightly down by 1.4 percentage points compared to the previous year [2]. Cost and Expense Analysis - The overall expense ratio increased, with sales, management, R&D, and financial expense ratios rising by 3.7 percentage points, 2.5 percentage points, 4.8 percentage points, and 1.4 percentage points respectively [2]. - The increase in management expenses was primarily due to higher labor and consulting service costs, while financial expenses were impacted by foreign exchange losses from overseas investments [2]. Product and Market Development - The company launched a new anti-aging product targeting high-net-worth individuals, aiming to lead the anti-aging market [3]. - The successful registration of a new cosmetic raw material and the approval of a minoxidil topical solution broaden the company's product diversity and drug development matrix [3]. - The company is enhancing its domestic market presence through a robust B2B channel network and leveraging self-media for operational efficiency and sales growth [3]. International Expansion - The new REGEN factory has commenced production, facilitating the international expansion of products like "Hi Body" and "Moisture White Angel" [3].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a decline in revenue and net profit for Q3 2025, with revenue of 1.87 billion yuan (down 21.5% year-on-year) and net profit of 1.09 billion yuan (down 31.1%) for the first three quarters of 2025. The Q3 revenue was 570 million yuan (down 21.3%) and net profit was 300 million yuan (down 34.6%). Due to increased market competition, the profit forecasts for 2025-2027 have been revised downwards [5] - The company has a rich product matrix and is accelerating its internationalization process, which, combined with its internal pipeline, is expected to enhance competitiveness and drive performance growth through both organic and external means. The current stock price corresponds to a reasonable valuation [5] - The company is seeking incremental market opportunities in the cosmetics sector, with new product launches and successful registrations of new cosmetic ingredients, which are expected to diversify its product offerings and enhance market presence [7] Financial Summary - For 2025, the company is expected to achieve revenue of 2.504 billion yuan (down 17.2% year-on-year) and a net profit of 1.48 billion yuan (down 24.4%). The projected EPS for 2025 is 4.89 yuan, with corresponding P/E ratios of 33.4, 27.6, and 23.6 for 2025, 2026, and 2027 respectively [8][10] - The gross margin for Q1-Q3 2025 was 93.4%, slightly down from 93.2% in Q3 2025, indicating a minor decline year-on-year. The overall expense ratios have increased, primarily due to rising labor and consulting service costs [6][11] Product and Market Strategy - The company launched a new anti-aging product targeting high-net-worth individuals, aiming to lead the development trend in the anti-aging sector. Additionally, a subsidiary received approval for a new drug, further diversifying the company's product development matrix [7] - The B-end channel network is a core competitive advantage for the company, leveraging its self-media platform to empower industry operators and drive sales growth through effective traffic management [7]